Flowchart of literature screening process. by Shangtian Wang (20933822)

Subjects:

Basic characteristics of included literature. by Shangtian Wang (20933822)

Subjects:

Raw data. by Shangtian Wang (20933822)

Subjects:

Forest plot of overall analysis results. by Shangtian Wang (20933822)

Subjects:

Forest plot for subgroups of infection types. by Shangtian Wang (20933822)

Subjects:

Sensitivity analysis results. by Shangtian Wang (20933822)

Subjects:

Forest plot for subgroups of analysis types. by Shangtian Wang (20933822)

Subjects:

Forest plot for subgroups of study types. by Shangtian Wang (20933822)

Subjects:

Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Subjects:

KEGG enrichment map of differential metabolites (a) and differential abundance score map (b). by Jun Sun (48981)

Subjects:

Detected metabolites (a), volcano plot (b) and scatter plot (c) of differential metabolites. by Jun Sun (48981)

Subjects:

Velar adhesion (VA). by Miki Kashiwagi (21439684)

Subjects:

Multivariate regression analysis to explain the decrease in visibility and palpability. by Miharu Matsumoto (21304390)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

The effectiveness of a warning label on carbonated beverage consumption for consumers with different habit strengths. by Yulian Ding (5984591)

Subjects:

Model A: Logistic structural model. by Abigail A. Lee (19935335)

“…Additionally, higher income slightly predicted decreased HPV vaccine hesitancy. All other latent variables and covariates were not significantly predictive of intent to vaccinate in the overall structural mode. …”

Box plots showing baseline prevalence and mean egg count at pre-MDA1 in districts that were responders compared to those that were persistent hotspots of decreasing praziquantel ef... by Takafira Mduluza (39754)

Sodium levels (mg/100 g) in matched restaurant menu items in 2016 and 2020 by UK NSRI food categories with ≥ 10 items. by Caroline G. Middleton (22041479)

Subjects: